Related Experiment Video
Updated: Jul 16, 2026
09:49
Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy
Published on: December 28, 2021
[Insulin-induced lipohypertrophy treated by liposuction].
A Brun1, J-P Comparin, D Voulliaume
1Service de chirurgie plastique reconstructrice et esthétique, centre des brûlés, centre hospitalier Saint-Joseph et Saint-Luc, 20, quai Claude-Bernard, 69365 Lyon, France. abrun78@free.fr
Annales De Chirurgie Plastique Et Esthetique
|March 27, 2007
Summary
Suction-assisted lipectomy effectively treats insulin injection site lipodystrophies. This procedure improves insulin absorption, reduces pain, and enhances aesthetics in diabetic patients.
Area of Science:
- Endocrinology
- Dermatology
- Plastic Surgery
Background:
- Insulin-dependent diabetes mellitus (IDDM) management requires insulin therapy.
- Insulin injections can cause lipodystrophies, leading to functional and aesthetic issues.
- These complications include pain, reduced treatment efficacy, hematomas, and edema at injection sites.
Observation:
- Two cases of IDDM patients with significant lipodystrophies were treated with suction-assisted lipectomy (SAL).
- Lipodystrophies affected thighs, abdomen, and shoulders.
- Treatment effectiveness was evaluated based on aesthetic improvement, insulin treatment efficiency, ease of injection, and pain reduction.
Findings:
- SAL resulted in a significant reduction in the insulin dose required for normoglycemia.
- Patients experienced improved pain control at injection sites.
- The procedure led to better management of hematomas and edema, alongside aesthetic enhancement.
Implications:
- Suction-assisted lipectomy is a simple and effective treatment for insulin-induced lipodystrophies.
- This intervention can improve the quality of life for diabetic patients undergoing insulin therapy.
- SAL offers a viable solution for managing injection site complications, optimizing diabetes care.
Related Concept Videos
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:24Overview of Lipid Metabolism
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:28Insulin: The Receptor and Signaling Pathways
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...